Protalix BioTherapeutics (PLX) Return on Capital Employed (2011 - 2026)
Protalix BioTherapeutics' quarterly Return on Capital Employed came in at 37.12% in Q1 2026, up 2774.0% year-on-year from 1.29% in Q1 2025, and up 1858.08% quarter-over-quarter from 2.11% in Q4 2025.
Protalix BioTherapeutics has reported Return on Capital Employed for 15 years, with the latest figure at 37.12% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2774.0% year-over-year to 37.12%; the trailing twelve-month figure through Mar 2026 stood at 37.12% (up 2774.0% YoY), and the FY2025 full-year result was 2.29%, down 964.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 37.12%, up from 2.11% in the prior quarter.
- The five-year high for Return on Capital Employed was 52.81% in Q3 2023, with the low at 66.57% in Q3 2022.
- Average Return on Capital Employed over 5 years is 1.49%, with a median of 9.36% recorded in 2024.
- Year-over-year, Return on Capital Employed jumped 11938 bps in 2023 and slumped 8627 bps in 2024.
- Tracing PLX's Return on Capital Employed over 5 years: stood at 12.69% in 2022, then jumped by 304 bps to 25.85% in 2023, then tumbled by 64 bps to 9.36% in 2024, then plunged by 123 bps to 2.11% in 2025, then jumped by 1858 bps to 37.12% in 2026.
- The last three Return on Capital Employed figures came in at 37.12% (Q1 2026), 2.11% (Q4 2025), and 10.9% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 37.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.12% |
| Dec 31, 2025 | -2.11% |
| Sep 30, 2025 | 10.90% |
| Jun 30, 2025 | 15.79% |
| Mar 31, 2025 | 9.38% |
| Dec 31, 2024 | 9.36% |
| Sep 30, 2024 | -17.02% |
| Jun 30, 2024 | -45.20% |
| Mar 31, 2024 | 24.96% |
| Dec 31, 2023 | 25.85% |
| Sep 30, 2023 | 52.81% |
| Jun 30, 2023 | 41.07% |
| Mar 31, 2023 | -12.18% |
| Dec 31, 2022 | -12.69% |
| Sep 30, 2022 | -66.57% |
| Jun 30, 2022 | -44.66% |
| Mar 31, 2022 | -52.18% |
| Dec 31, 2021 | -45.07% |
| Sep 30, 2021 | -22.45% |
| Jun 30, 2021 | -136.35% |
| Mar 31, 2021 | -126.34% |
| Dec 31, 2020 | -16.57% |
| Sep 30, 2020 | 7.37% |
| Jun 30, 2020 | 8.91% |
| Mar 31, 2020 | -2.97% |
| Dec 31, 2019 | -114.19% |
| Sep 30, 2019 | -78.37% |
| Jun 30, 2019 | -58.43% |
| Mar 31, 2019 | -57.83% |
| Dec 31, 2018 | -50.70% |
| Sep 30, 2018 | -73.31% |
| Jun 30, 2018 | -73.53% |
| Mar 31, 2018 | -75.08% |
| Dec 31, 2017 | -78.66% |
| Sep 30, 2017 | -100.65% |
| Jun 30, 2017 | -70.26% |
| Mar 31, 2017 | -55.79% |
| Dec 31, 2016 | -326.78% |
| Sep 30, 2016 | -49.96% |
| Jun 30, 2016 | -42.58% |
| Mar 31, 2016 | -31.51% |
| Mar 31, 2014 | -44.25% |
| Dec 31, 2013 | -37.62% |
| Sep 30, 2013 | -40.80% |
| Jun 30, 2013 | -68.49% |
| Mar 31, 2013 | -21.10% |
| Dec 31, 2012 | -23.27% |
| Sep 30, 2012 | -17.98% |
| Jun 30, 2012 | -25.56% |
| Mar 31, 2012 | -88.56% |
| Dec 31, 2011 | -97.09% |
| Sep 30, 2011 | -76.01% |